NCT05670782 - A Study to Evaluate Safety and Efficacy of KM-819 in Healthy Adults and Participants with Parkinson's Disease | Biotech Hunter

Enrollment

314

Participants

Timeline

Start Date

July 19, 2022

Primary Completion Date

October 30, 2025

Study Completion Date

November 13, 2025

Conditions

Parkinson Disease

Interventions

DRUG

KM-819

Participants will receive oral doses of KM-819 once-daily

DRUG

Placebo

Participants will receive matching placebo once-daily

Trial Locations (3)

Quest Research Institute, Rose Cancer Center, Royal Oak

Parexel Early Phase Clinical Unit, Glendale

University California San Diego Medical Center, San Diego